Diagnostic role of Xpert-MTB RIF assay in osteoarticular tuberculosis: A retrospective study.
Composite reference standard
Extrapulmonary
Gene Xpert assay
Osteoarticular
Tuberculosis
Journal
World journal of orthopedics
ISSN: 2218-5836
Titre abrégé: World J Orthop
Pays: United States
ID NLM: 101576349
Informations de publication
Date de publication:
18 Mar 2022
18 Mar 2022
Historique:
received:
11
10
2021
revised:
11
12
2022
accepted:
27
01
2022
entrez:
23
3
2022
pubmed:
24
3
2022
medline:
24
3
2022
Statut:
epublish
Résumé
Osteoarticular tuberculosis (OATB) is a severe form of extrapulmonary tuberculosis (TB), which causes notable morbidity and warrants a high index of suspicion for prompt management. The diagnosis of OATB poses a challenge, because of the difficulty of collecting the samples and, secondarily, the paucibacillary nature of lesion, which gives poor sensitivity and reproducibility, with long turnaround time of routine/conventional laboratory tests and the requirement for invasive procedures and expertise. The Xpert MTB/RIF assay has been approved by the World Health Organization as a rapid diagnostic tool for diagnosing pulmonary and extrapulmonary TB. To emphasize the diagnostic efficiency of gene Xpert for OATB in suspected patients in a tertiary care hospital of Eastern India. This retrospective study was conducted in the Department of Microbiology and Orthopaedics by analyzing the data of the gene Xpert assay over a 3-year duration from January 2018 to February 2021. Demographic and clinical data were recorded. The diagnostic efficiency of gene Xpert was evaluated against the composite reference standard (CRS). A total of 37 cases fell into positive, probable, and possible categories of osteoarticular TB out of 112 patients included in the study by CRS; gene Xpert result was positive in 35 out of the 37 different CRS categorized cases. Of the 112 cases, culture was put in 40 cases, and, of these cultures, 5 cases showed the growth of MTB. Of these, 4 cases were included in the 35 cases diagnosed by gene Xpert. Smear microscopy was positive in 6 out of 37 CRS categorized cases. When compared with CRS, the sensitivity of gene Xpert assay, culture, and smear was found to be 94.6%, 13.5%, and 16.2%, respectively, while specificity in all the three types of tests was 100%. When kappa statistics were applied, the percentage of agreement gene Xpert, culture, and microscopy with CRS was found to be 95%, 20%, and 22.6%, respectively. Follow-up of the gene Xpert positive patients after getting anti-tubercular treatment revealed improved conditions. Gene Xpert could detect 31 extra cases with a low and very low mycobacterial load that were missed by the routine culture methods. Hence, more samples should be processed for molecular diagnostic methods like gene Xpert along with other conventional methods for the validation of the molecular test prospectively for the timely diagnosis of osteoarticular TB.
Sections du résumé
BACKGROUND
BACKGROUND
Osteoarticular tuberculosis (OATB) is a severe form of extrapulmonary tuberculosis (TB), which causes notable morbidity and warrants a high index of suspicion for prompt management. The diagnosis of OATB poses a challenge, because of the difficulty of collecting the samples and, secondarily, the paucibacillary nature of lesion, which gives poor sensitivity and reproducibility, with long turnaround time of routine/conventional laboratory tests and the requirement for invasive procedures and expertise. The Xpert MTB/RIF assay has been approved by the World Health Organization as a rapid diagnostic tool for diagnosing pulmonary and extrapulmonary TB.
AIM
OBJECTIVE
To emphasize the diagnostic efficiency of gene Xpert for OATB in suspected patients in a tertiary care hospital of Eastern India.
METHODS
METHODS
This retrospective study was conducted in the Department of Microbiology and Orthopaedics by analyzing the data of the gene Xpert assay over a 3-year duration from January 2018 to February 2021. Demographic and clinical data were recorded. The diagnostic efficiency of gene Xpert was evaluated against the composite reference standard (CRS).
RESULTS
RESULTS
A total of 37 cases fell into positive, probable, and possible categories of osteoarticular TB out of 112 patients included in the study by CRS; gene Xpert result was positive in 35 out of the 37 different CRS categorized cases. Of the 112 cases, culture was put in 40 cases, and, of these cultures, 5 cases showed the growth of MTB. Of these, 4 cases were included in the 35 cases diagnosed by gene Xpert. Smear microscopy was positive in 6 out of 37 CRS categorized cases. When compared with CRS, the sensitivity of gene Xpert assay, culture, and smear was found to be 94.6%, 13.5%, and 16.2%, respectively, while specificity in all the three types of tests was 100%. When kappa statistics were applied, the percentage of agreement gene Xpert, culture, and microscopy with CRS was found to be 95%, 20%, and 22.6%, respectively. Follow-up of the gene Xpert positive patients after getting anti-tubercular treatment revealed improved conditions.
CONCLUSION
CONCLUSIONS
Gene Xpert could detect 31 extra cases with a low and very low mycobacterial load that were missed by the routine culture methods. Hence, more samples should be processed for molecular diagnostic methods like gene Xpert along with other conventional methods for the validation of the molecular test prospectively for the timely diagnosis of osteoarticular TB.
Identifiants
pubmed: 35317258
doi: 10.5312/wjo.v13.i3.289
pmc: PMC8935335
doi:
Types de publication
Journal Article
Langues
eng
Pagination
289-296Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: There is no conflict of interest.
Références
Yonsei Med J. 2004 Jun 30;45(3):453-61
pubmed: 15227732
Eur Respir J. 2014 Oct;44(4):1090-3
pubmed: 25063241
Health Qual Life Outcomes. 2018 Feb 13;16(1):34
pubmed: 29439718
Rom J Morphol Embryol. 2005;46(1):67-72
pubmed: 16286988
Int J Infect Dis. 2015 Jul;36:27-30
pubmed: 26004172
PLoS One. 2018 Jun 1;13(6):e0198600
pubmed: 29856840
Eur Spine J. 2017 Dec;26(12):3162-3169
pubmed: 28391384
Sci Rep. 2019 Jul 30;9(1):11053
pubmed: 31363115
Indian J Med Res. 2004 Oct;120(4):316-53
pubmed: 15520485
Curr Health Sci J. 2017 Jul-Sep;43(3):171-190
pubmed: 30595874
Ann Intern Med. 2015 Feb 17;162(4):JC11
pubmed: 25686186
J Med Assoc Thai. 2009 Mar;92 Suppl 2:S101-9
pubmed: 19562993
J Bone Joint Surg Br. 2004 Aug;86(6):901-4
pubmed: 15330034
J Clin Microbiol. 2000 Mar;38(3):1203-8
pubmed: 10699023